Evaluation of circulating PD-1 and PD-L1 as diagnostic biomarkers in dogs with tumors

BackgroundProgrammed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) have important roles in tumor evasion of the immune system.ObjectivesThis study aimed to assess the diagnostic utility of circulating PD-1 and PD-L1 levels in healthy dogs and dogs with tumors.MethodsCirculating PD-1 and PD-L1 levels in the serum of 71 dogs with tumors were compared with those of 52 healthy dogs by performing enzyme-linked immunosorbent assay (ELISA).ResultsThe ELISA results revealed higher circulating PD-1 and PD-L1 levels in dogs with tumors (2.9 2.2–3.7] ng/mL; median IQR] and 2.4 1.4–4.4] ng/mL, respectively) than in healthy dogs (2.4 1.9–3.0] ng/mL; p = 0.012 and 1.4 0.9–2.1] ng/mL; p < 0.001, respectively). Especially, there was a significant difference in circulating PD-1 levels between healthy dogs and dogs with malignant epithelial tumors (2.4 1.9–3.0] ng/mL and 3.1 2.6–4.4] ng/mL, respectively; p < 0.01). In addition, there was a significant difference in circulating PD-L1 levels between healthy dogs and dogs with lymphomas (1.4 0.9–2.1] ng/mL and 2.7 1.6–5.8] ng/mL, respectively; p < 0.001).ConclusionThis study indicates that circulating PD-1 and PD-L1 have potential as tumor diagnostic biomarkers in dogs with tumors.